Luminal Breast Carcinoma disease: Malacards - Research Articles, Drugs, Genes, Clinical Trials

MCID: LMN006 MIFTS: 38	Luminal Breast Carcinoma Categories: Cancer diseases
Genes Tissues Related diseases Publications Pathways Drugs Expand all tables

Sources

Aliases & Classifications for Luminal Breast Carcinoma

MalaCards integrated aliases for Luminal Breast Carcinoma:

Name: Luminal Breast Carcinoma ¹² ¹⁵

Breast Tumor Luminal ¹² ¹⁷

Luminal Breast Cancer ¹²

Classifications:

MalaCards categories:
Global: Cancer diseases

See all MalaCards categories (disease lists)

External Ids:

Disease Ontology ¹² DOID:0060548

EFO ¹⁷ EFO_0000306

Sources

Summaries for Luminal Breast Carcinoma

MalaCards based summary : Luminal Breast Carcinoma, also known as breast tumor luminal, is related to breast ductal carcinoma and in situ carcinoma. An important gene associated with Luminal Breast Carcinoma is MTOR (Mechanistic Target Of Rapamycin Kinase), and among its related pathways/superpathways are Pathways in cancer and Development HGF signaling pathway. The drugs Letrozole and Vitamin D have been mentioned in the context of this disorder. Affiliated tissues include breast, bone and testes, and related phenotypes are Decreased viability and Decreased viability

Sources

Related Diseases for Luminal Breast Carcinoma

Diseases related to Luminal Breast Carcinoma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 134)

#	Related Disease	Score	Top Affiliating Genes
1	breast ductal carcinoma	30.7	PGR ESR1 ERBB2
2	in situ carcinoma	30.1	PGR KRT5 ESR1 ERBB2
3	breast adenocarcinoma	29.7	PIK3CA ESR1 ERBB2 AKT1
4	ductal carcinoma in situ	29.4	PGR KRT5 ESR1 ERBB2 AKT1
5	estrogen-receptor positive breast cancer	29.1	PIK3CA PGR MTOR FOXA1 ESR1 ERBB2
6	breast cancer	26.5	ZNF703 PIK3CA PGR MTOR KRT5 GATA3
7	bartholin's gland adenoma	10.7	PGR ESR1
8	vestibular gland benign neoplasm	10.7	PGR ESR1
9	lung leiomyoma	10.7	PGR ESR1
10	vulvar syringoma	10.7	PGR ESR1
11	breast apocrine carcinoma	10.7	PGR ERBB2
12	scirrhous adenocarcinoma	10.7	PGR ERBB2
13	vulvar leiomyoma	10.7	PGR ESR1
14	trigonitis	10.6	PGR ESR1
15	vulvar benign neoplasm	10.6	PGR ESR1
16	comedo carcinoma	10.6	ESR1 ERBB2
17	intracystic papillary adenoma	10.6	PGR ERBB2
18	predominantly cortical thymoma	10.6	PGR ESR1
19	oncocytic breast carcinoma	10.6	PGR ESR1
20	bartholin's gland benign neoplasm	10.6	PGR ESR1
21	progesterone-receptor negative breast cancer	10.6	PGR ERBB2
22	endometrial squamous cell carcinoma	10.6	PGR ESR1
23	progesterone resistance	10.6	PGR ESR1
24	adenoid basal cell carcinoma	10.6	PGR ESR1
25	endometrial mucinous adenocarcinoma	10.5	PGR ESR1
26	dermatosis papulosa nigra	10.5	PIK3CA MTOR
27	breast cystic hypersecretory carcinoma	10.5	KRT5 ERBB2
28	synchronous bilateral breast carcinoma	10.5	PGR ESR1
29	diffuse peritoneal leiomyomatosis	10.5	PGR ESR1
30	deep angioma	10.5	PGR ESR1
31	large cell acanthoma	10.5	MTOR KRT5
32	gender identity disorder	10.5	PGR ESR1
33	peritoneal benign neoplasm	10.5	PGR ESR1
34	pancreatic neuroendocrine tumor	10.5	PIK3CA MTOR
35	inverted transitional papilloma	10.5	KRT5 GATA3
36	glassy cell carcinoma of the cervix	10.5	PGR ESR1 ERBB2
37	angiomyolipoma	10.5	PGR MTOR ESR1
38	breast scirrhous carcinoma	10.5	PGR ESR1 ERBB2
39	breast medullary carcinoma	10.5	PGR ESR1 ERBB2
40	progesterone-receptor positive breast cancer	10.5	PGR ESR1 ERBB2
41	cervical carcinosarcoma	10.5	PGR ESR1
42	breast adenoid cystic carcinoma	10.5	PGR ESR1 ERBB2
43	inflammatory breast carcinoma	10.4	PGR ESR1 ERBB2
44	lymphangioleiomyomatosis	10.4	PGR MTOR ESR1
45	mammary paget's disease	10.4	PGR ESR1 ERBB2
46	tubular adenocarcinoma	10.4	PGR ESR1 ERBB2
47	fallopian tube carcinoma	10.4	PGR ESR1 ERBB2
48	female reproductive endometrioid cancer	10.4	PGR ESR1
49	breast fibroadenoma	10.4	PGR ESR1 ERBB2
50	uterine corpus serous adenocarcinoma	10.4	PIK3CA ERBB2

Graphical network of the top 20 diseases related to Luminal Breast Carcinoma:

Sources

Symptoms & Phenotypes for Luminal Breast Carcinoma

GenomeRNAi Phenotypes related to Luminal Breast Carcinoma according to GeneCards Suite gene sharing:

²⁶

#	Description	GenomeRNAi Source Accession	Score	Top Affiliating Genes
1	Decreased viability	GR00055-A-2	9.68	MTOR PIK3CA
2	Decreased viability	GR00221-A-1	9.68	AKT1 ESR1 MTOR PIK3CA
3	Decreased viability	GR00221-A-2	9.68	AKT1 ESR1 PIK3CA
4	Decreased viability	GR00221-A-3	9.68	AKT1 ERBB2
5	Decreased viability	GR00221-A-4	9.68	AKT1 ERBB2 ESR1 MTOR PIK3CA
6	Decreased viability	GR00342-S-1	9.68	MTOR
7	Decreased viability	GR00342-S-2	9.68	MTOR
8	Decreased viability	GR00402-S-2	9.68	AKT1 ERBB2 ESR1 MTOR PIK3CA

MGI Mouse Phenotypes related to Luminal Breast Carcinoma:

⁴⁶ (show all 16)

#	Description	MGI Source Accession	Score	Top Affiliating Genes
1	cellular	MP:0005384	10.28	AKT1 CD44 ERBB2 ESR1 GATA3 HORMAD1
2	growth/size/body region	MP:0005378	10.24	AKT1 CD44 ERBB2 ESR1 FOXA1 GATA3
3	homeostasis/metabolism	MP:0005376	10.22	AKT1 CD44 ERBB2 ESR1 FOXA1 GATA3
4	behavior/neurological	MP:0005386	10.21	AKT1 CD44 ERBB2 ESR1 KRT5 MTOR
5	endocrine/exocrine gland	MP:0005379	10.21	AKT1 CD44 ERBB2 ESR1 FOXA1 GATA3
6	immune system	MP:0005387	10.16	AKT1 CD44 ESR1 FOXA1 GATA3 KDM4C
7	cardiovascular system	MP:0005385	10.15	AKT1 CD44 ERBB2 ESR1 GATA3 MTOR
8	mortality/aging	MP:0010768	10.14	AKT1 CD44 ERBB2 ESR1 FOXA1 GATA3
9	embryo	MP:0005380	10.13	AKT1 ERBB2 ESR1 GATA3 HORMAD1 MTOR
10	integument	MP:0010771	10.09	AKT1 CD44 ERBB2 ESR1 FOXA1 GATA3
11	muscle	MP:0005369	9.97	AKT1 CD44 ERBB2 ESR1 GATA3 MTOR
12	neoplasm	MP:0002006	9.92	AKT1 CD44 ERBB2 ESR1 FOXA1 KDM4C
13	no phenotypic analysis	MP:0003012	9.8	ESR1 GATA3 KDM4C KRT5 MTOR PGR
14	normal	MP:0002873	9.7	AKT1 CD44 ERBB2 ESR1 GATA3 MTOR
15	reproductive system	MP:0005389	9.56	AKT1 CD44 ERBB2 ESR1 GATA3 HORMAD1
16	skeleton	MP:0005390	9.23	AKT1 CD44 ERBB2 ESR1 GATA3 MTOR

Sources

Drugs & Therapeutics for Luminal Breast Carcinoma

Drugs for Luminal Breast Carcinoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 56)

Name

Status

Phase

Clinical Trials

Cas Number

PubChem Id

Letrozole

Approved, Investigational

Phase 4

112809-51-5

3902

Vitamin D

Approved, Nutraceutical, Vet_approved

Phase 4

1406-16-2

Calcium

Approved, Nutraceutical

Phase 4

7440-70-2

271

Estrogens

Phase 4

Hormones

Phase 4

Steroid Synthesis Inhibitors

Phase 4

Hormone Antagonists

Phase 4

Estrogen Receptor Antagonists

Phase 4

Hormones, Hormone Substitutes, and Hormone Antagonists

Phase 4

Aromatase Inhibitors

Phase 4

Estrogen Antagonists

Phase 4

Calcium, Dietary

Phase 4

Calciferol

Phase 4

Palbociclib

Approved, Investigational

Phase 3

571190-30-2

5330286 11431660 5005498

Goserelin

Approved

Phase 3

65807-02-5, 1233494-97-7

47725 5311128

Fulvestrant

Approved, Investigational

Phase 3

129453-61-8

104741 17756771

Protein Kinase Inhibitors

Phase 3

Doxorubicin

Approved, Investigational

Phase 2

23214-92-8

31703

Tamoxifen

Approved

Phase 2

10540-29-1

2733526

Anastrozole

Approved, Investigational

Phase 2

120511-73-1

2187

Exemestane

Approved, Investigational

Phase 2

107868-30-4

60198

Capecitabine

Approved, Investigational

Phase 2

154361-50-9

60953

Lenvatinib

Approved, Investigational

Phase 2

417716-92-8

Phenobarbital

Approved, Investigational

Phase 2

50-06-6

4763

Paclitaxel

Approved, Vet_approved

Phase 2

33069-62-4

36314

Docetaxel

Approved, Investigational

Phase 2

114977-28-5

148124

Cyclophosphamide

Approved, Investigational

Phase 2

50-18-0, 6055-19-2

2907

Epirubicin

Approved

Phase 2

56420-45-2

41867

Liposomal doxorubicin

Phase 2

31703

Selective Estrogen Receptor Modulators

Phase 2

Estrogen Receptor Modulators

Phase 2

Bone Density Conservation Agents

Phase 2

taxane

Phase 2

Cytochrome P-450 CYP3A Inducers

Phase 2

Neurotransmitter Agents

Phase 2

Antineoplastic Agents, Phytogenic

Phase 2

Central Nervous System Depressants

Phase 2

GABA Agents

Phase 2

Cytochrome P-450 Enzyme Inducers

Phase 2

Albumin-Bound Paclitaxel

Phase 2

Tubulin Modulators

Phase 2

Hypnotics and Sedatives

Phase 2

GABA Modulators

Phase 2

Excitatory Amino Acid Antagonists

Phase 2

Anticonvulsants

Phase 2

Excitatory Amino Acids

Phase 2

Antimitotic Agents

Phase 2

Alkylating Agents

Phase 2

Immunologic Factors

Phase 2

Anti-Bacterial Agents

Phase 2

Interventional clinical trials:

(show all 12)

#	Name	Status	NCT ID	Phase	Drugs
1	Hormone Therapy Initiation Immediately After Histological Diagnosis of Breast Cancer, Can it Make Any Difference?	Not yet recruiting	NCT03111615	Phase 4	Aromatase Inhibitors
2	Multicentre, International Neoadjuvant Randomized Double-blind Trial Comparing Fulvestrant® to a Combination of Fulvestrant® and Palbociclib (CDK 4/6 Inhibitor) in Patients With Operable Luminal Breast Cancer Responding to Fulvestrant®	Recruiting	NCT03447132	Phase 3	Fulvestrant 500mg;Palbociclib 125mg;Goserelin 3.6 MG;Placebos
3	A Phase II Exploratory, Open-label, Single Arm Study of BYL719 Monotherapy, a Selective Phosphatidylinositol 3-kinase (PI3K) Alpha Inhibitor, in Adult Patients With Advanced Breast Cancer Progressing After First Line Therapy.	Unknown status	NCT02506556	Phase 2	BYl719
4	Phase Ib Followed by Phase II Study of Pre-operative Treatment With Lenvatinib Combined With Letrozole in Post-menopausal Women With Newly Diagnosed Hormone Receptor Positive Breast Cancer With Measurable Primary Breast Tumor	Unknown status	NCT02562118	Phase 1, Phase 2	Lenvatinib + Letrozole
5	Tailoring NEOadjuvant Therapy in Hormone Receptor Positive, HER2 Negative, Luminal Breast Cancer.	Recruiting	NCT03283384	Phase 2	Letrozole;Chemotherapy;Ribociclib plus letrozole
6	Comparative Study for the Degree of Biological Changes After Short-term 2 Weeks and 4 Weeks Preoperative Endocrine Therapy in Luminal Breast Cancer	Recruiting	NCT04023292	Phase 2	Endocrine therapy;Endocrine therapy
7	Group Sequential Response Adaptive Randomized Clinical Trial of Concomitant Chemotherapy Plus Endocrine Therapy Versus Cyclin-dependent Kinase 4/6 (CDK4/6) Inhibitor Plus Endocrine Therapy for Advanced Hormone Receptor-positive, HER2-negative Breast Cancer.	Recruiting	NCT03227328	Phase 2	concomitant cyclin-dependent Kinase 4/6 (CDK4/6) inhibitor plus endocrine therapy;chemotherapy plus endocrine therapy (administered either concomitantly or sequentially)
8	A Phase II Window-of-opportunity Study of Single Agent Lenvatinib in Estrogen Receptor Positive Early Stage Breast Cancer	Recruiting	NCT03168074	Phase 2	lenvatinib
9	Phase II, Open-label, Non-randomized Study of Nab-paclitaxel for the Neoadjuvant Treatment of Patients With Stage II and III Luminal Breast Cancer	Active, not recruiting	NCT01565499	Phase 2	Nab-paclitaxel
10	Open-label, Randomized, Multicenter, International, Parallel Exploratory Phase II Study, Comparing 3 FEC-3 Docetaxel Chemotherapy to Letrozole + Palbociclib Combination as Neoadjuvant Treatment of Stage II-IIIA PAM 50 ROR-defined Low or Intermediate Risk Luminal Breast Cancer, in Postmenopausal Women	Active, not recruiting	NCT02400567	Phase 2	Fluorouracile;Epirubicin;Cyclophosphamide;Letrozole;Palbociclib
11	Immediate Breast Reconstruction With Free Greater Omentum for Luminal Breast Cancer Patients	Recruiting	NCT03370250
12	Adjuvant Endocrine Therapy in Early Stage Breast Cancer: Impact of Drug Adherence/Persistence on Clinical Outcome in Various Breast Cancer Subtypes	Not yet recruiting	NCT03761420

Search NIH Clinical Center for Luminal Breast Carcinoma

Sources

Genetic Tests for Luminal Breast Carcinoma

Sources

Anatomical Context for Luminal Breast Carcinoma

MalaCards organs/tissues related to Luminal Breast Carcinoma:

⁴¹

Breast, Bone, Testes

Sources

Publications for Luminal Breast Carcinoma

Articles related to Luminal Breast Carcinoma:

(show all 14)

#	Title	Authors	PMID	Year
1	DDR1 and MT1-MMP Expression Levels Are Determinant for Triggering BIK-Mediated Apoptosis by 3D Type I Collagen Matrix in Invasive Basal-Like Breast Carcinoma Cells. ³⁸	Saby C...Morjani H	31130862	2019
2	First French Pilot Quality Assessment of the EndoPredict Test for Early Luminal Breast Carcinoma. ³⁸	Lehmann-Che J...GFCO GROUP	29715116	2018
3	Age-related modifications of type I collagen impair DDR1-induced apoptosis in non-invasive breast carcinoma cells. ³⁸	Saby C...Morjani H	29733741	2018
4	Inverse relationship between Ki67 and survival in early luminal breast cancer: confirmation in a multivariate analysis. ³⁸	Gallardo A...Lerma E	28865009	2018
5	Separase is a marker for prognosis and mitotic activity in breast cancer. ³⁸	Gurvits N...Talvinen K	28859055	2017
6	Nomogram Model of LNR Predicts Survival in Premenopausal Patients with Node-positive Luminal Breast Cancer. ³⁸	Qin T...Wang S	28739755	2017
7	FBP1 expression is associated with basal-like breast carcinoma. ³⁸	Shi L...Zhang Q	28529559	2017
8	Comparison of visual assessment and image analysis in the evaluation of Ki-67 expression and their prognostic significance in immunohistochemically defined luminal breast carcinoma. ³⁸	Arihiro K...Kobayashi Y	27511992	2016
9	Altered PPP2R2A and Cyclin D1 expression defines a subgroup of aggressive luminal-like breast cancer. ³⁸	Beca F...Schmitt F	25879784	2015
10	TFAP2C governs the luminal epithelial phenotype in mammary development and carcinogenesis. ³⁸	Cyr AR...Weigel RJ	24469049	2015
11	p-mTOR expression is associated with better prognosis in luminal breast carcinoma. ³⁸	Beca F...Schmitt F	25053543	2014
12	Genomic instability: a stronger prognostic marker than proliferation for early stage luminal breast carcinomas. ³⁸	Vincent-Salomon A...Delattre O	24143191	2013
13	Her2 negative luminal breast carcinoma and Ki-67 evaluation. ³⁸	Pavlakis K...Barbounis V	22647834	2012
14	Modeling of response to endocrine therapy in a panel of human luminal breast cancer xenografts. ³⁸	Cottu P...Decaudin D	22002565	2012

Sources

Genes for Luminal Breast Carcinoma

Genes related to Luminal Breast Carcinoma (0 elite genes):

(show all 15)

- Elite gene

- Cancer Census gene in COSMIC

#	Symbol	Description	Category	Score	Evidence
1	MTOR	Mechanistic Target Of Rapamycin Kinase	Protein Coding	20.05	DISEASES inferred ¹⁵ GeneCards inferred via : Publications (show sections)
2	KDM4C	Lysine Demethylase 4C	Protein Coding	16.84	DISEASES inferred ¹⁵ ¹⁵
3	ESR1	Estrogen Receptor 1	Protein Coding	16.8	DISEASES inferred ¹⁵
4	ERBB2	Erb-B2 Receptor Tyrosine Kinase 2	Protein Coding	16.78	DISEASES inferred ¹⁵
5	PGR	Progesterone Receptor	Protein Coding	15.92	DISEASES inferred ¹⁵
6	PREX1	Phosphatidylinositol-3,4,5-Trisphosphate Dependent Rac Exchange Factor 1	Protein Coding	15.66	DISEASES inferred ¹⁵
7	FOXA1	Forkhead Box A1	Protein Coding	15.42	DISEASES inferred ¹⁵
8	GATA3	GATA Binding Protein 3	Protein Coding	15.34	DISEASES inferred ¹⁵
9	KRT5	Keratin 5	Protein Coding	15.24	DISEASES inferred ¹⁵
10	PIK3CA	Phosphatidylinositol-4,5-Bisphosphate 3-Kinase Catalytic Subunit Alpha	Protein Coding	15.03	DISEASES inferred ¹⁵
11	AKT1	AKT Serine/Threonine Kinase 1	Protein Coding	14.89	DISEASES inferred ¹⁵
12	HORMAD1	HORMA Domain Containing 1	Protein Coding	14.81	DISEASES inferred ¹⁵
13	CD44	CD44 Molecule (Indian Blood Group)	Protein Coding	14.77	DISEASES inferred ¹⁵
14	ELF5	E74 Like ETS Transcription Factor 5	Protein Coding	5.75	DISEASES inferred ¹⁵
15	ZNF703	Zinc Finger Protein 703	Protein Coding	5.73	DISEASES inferred ¹⁵

Sources

Variations for Luminal Breast Carcinoma

Sources

Expression for Luminal Breast Carcinoma

Search GEO for disease gene expression data for Luminal Breast Carcinoma.

Sources

Pathways for Luminal Breast Carcinoma

Pathways related to Luminal Breast Carcinoma according to GeneCards Suite gene sharing:

(show all 50)

#	Super pathways	Score	Top Affiliating Genes
1	Pathways in cancer ³⁷	12.74	PIK3CA MTOR ESR1 ERBB2 AKT1
2	Development HGF signaling pathway ²² Show member pathways Apoptosis and survival Anti-apoptotic action of membrane-bound ESR1 ²² Apoptosis and survival NGF signaling pathway ²² Apoptosis and survival Role of CDK5 in neuronal death and survival ²² Development Neurotrophin family signaling ²² MET activates PTPN11 ⁶⁶ MET activates STAT3 ⁶⁶ Neurotrophin signaling pathway ³⁷ Signaling events mediated by Hepatocyte Growth Factor Receptor (c-Met) ¹ Signaling of Hepatocyte Growth Factor Receptor ¹	12.59	PIK3CA MTOR ESR1 ERBB2 AKT1
3	Glioma ³⁷ Show member pathways Endocrine resistance ³⁷ Melanoma ³⁷ Non-small cell lung cancer ³⁷ Signaling Pathways in Glioblastoma ¹	12.57	PIK3CA MTOR ESR1 ERBB2 AKT1
4	ErbB signaling pathway ³⁷ ¹ Show member pathways EGFR Inhibitor Pathway, Pharmacodynamics ⁶¹ EGFR tyrosine kinase inhibitor resistance ³⁷ Renal cell carcinoma ³⁷ TCA Cycle Nutrient Utilization and Invasiveness of Ovarian Cancer ¹	12.53	PIK3CA MTOR ERBB2 AKT1
5	MicroRNAs in cancer ³⁷	12.47	PIK3CA MTOR ERBB2 CD44
6	mTOR signaling pathway (KEGG) ³⁷ Show member pathways mTOR Signaling Pathway ⁶⁵	12.44	PIK3CA MTOR ERBB2 AKT1
7	Gastric cancer ³⁷ Show member pathways Breast cancer ³⁷ Hepatocellular carcinoma ³⁷	12.4	PIK3CA PGR MTOR ESR1 ERBB2 AKT1
8	Apoptosis Pathway ⁷¹ Show member pathways Akt Pathway ⁷¹ NF-kappaB Pathway ⁷¹	12.38	PIK3CA MTOR ERBB2 AKT1
9	Development VEGF signaling via VEGFR2 - generic cascades ²² Show member pathways Development VEGF signaling and activation ²² VEGF - VEGF R2 Signaling Pathways ⁶⁵	12.32	PIK3CA ESR1 CD44 AKT1
10	Development IGF-1 receptor signaling ²² Show member pathways IL-4 Signaling Pathway ¹ Immune response IL-4 signaling pathway ²² Signal transduction AKT signaling ²²	12.31	PIK3CA MTOR GATA3 AKT1
11	Development Ligand-independent activation of ESR1 and ESR2 ²² Show member pathways Transcription CREB pathway ²² Transcription PPAR Pathway ²²	12.21	PIK3CA ESR1 ERBB2 AKT1
12	MAPK Signaling: Mitogen Stimulation Pathway ⁶⁵ Show member pathways Akt Signaling Pathway ⁶⁵	12.15	PIK3CA MTOR ERBB2 AKT1
13	Autophagy - animal ³⁷	12.02	PIK3CA MTOR AKT1
14	AKT Signaling Pathway ⁶⁷	12.02	PIK3CA MTOR ERBB2 AKT1
15	Transcription Androgen Receptor nuclear signaling ²² Show member pathways Translation Non-genomic (rapid) action of Androgen Receptor ²²	12	PIK3CA MTOR ERBB2 AKT1
16	MAPK Pathway ⁷¹ Show member pathways Toll-like Receptor Pathway ⁷¹	11.96	PIK3CA ERBB2 AKT1
17	DNA Damage Response (only ATM dependent) ¹	11.93	PIK3CA ERBB2 AKT1
18	Insulin resistance ³⁷ Show member pathways protein O-[N-acetyl]-glucosylation ¹	11.9	PIK3CA MTOR AKT1
19	Prolactin Signaling Pathway ¹ ³⁷ Show member pathways Development Prolactin receptor signaling ²² Leptin signaling pathway ¹	11.88	PIK3CA MTOR ESR1 ERBB2 ELF5 AKT1
20	ErbB1 downstream signaling ¹	11.87	PIK3CA MTOR AKT1
21	Type II diabetes mellitus ¹ ³⁷ Show member pathways Anti-diabetic Drug Potassium Channel Inhibitors Pathway, Pharmacodynamics ⁶¹	11.84	PIK3CA MTOR AKT1
22	TGF-beta Signaling Pathways ⁶⁵	11.84	MTOR ESR1 AKT1
23	Thyroid hormone signaling pathway ³⁷	11.83	PIK3CA MTOR ESR1 AKT1
24	Jak-Stat Signaling Pathway (sino) ⁶⁷	11.82	PIK3CA MTOR AKT1
25	Glucocorticoid receptor regulatory network ¹	11.76	KRT5 GATA3 AKT1
26	Signaling by ERBB4 ⁶⁶ Show member pathways Downregulation of ERBB4 signaling ⁶⁶ ErbB4 signaling events ¹ Nuclear signaling by ERBB4 ⁶⁶	11.74	PIK3CA PGR ESR1 ERBB2
27	Regulation of nuclear SMAD2/3 signaling ¹	11.71	GATA3 ESR1 AKT1
28	CXCR4-mediated signaling events ¹	11.7	PIK3CA MTOR AKT1
29	Sterol Regulatory Element-Binding Proteins (SREBP) signalling ¹	11.68	PIK3CA MTOR AKT1
30	Platinum drug resistance ³⁷	11.68	PIK3CA ERBB2 AKT1
31	HIF-1 signaling pathway ³⁷	11.66	PIK3CA MTOR ERBB2 AKT1
32	Human Thyroid Stimulating Hormone (TSH) signaling pathway ¹	11.63	PIK3CA MTOR AKT1
33	IL2 signaling events mediated by PI3K ¹ Show member pathways IL2 signaling events mediated by STAT5 ¹	11.61	PIK3CA MTOR AKT1
34	Regulation of Telomerase ¹	11.6	MTOR ESR1 AKT1
35	Pathways Affected in Adenoid Cystic Carcinoma ¹	11.59	PIK3CA ERBB2 AKT1
36	IL4-mediated signaling events ¹	11.57	PIK3CA MTOR AKT1
37	IL-2 Gene Expression in Activated and Quiescent T-Cells ⁶⁴ Show member pathways TOB in T-Cell Signaling ⁶⁴	11.56	PIK3CA ERBB2 AKT1
38	Proteoglycans in cancer ³⁷	11.41	PIK3CA MTOR ESR1 ERBB2 CD44 AKT1
39	Thymic Stromal LymphoPoietin (TSLP) Signaling Pathway ¹	11.4	PIK3CA MTOR AKT1
40	G-protein signaling_Cross-talk between Ras-family GTPases ²²	11.34	PIK3CA MTOR ERBB2 AKT1
41	Central carbon metabolism in cancer ³⁷	11.3	PIK3CA MTOR ERBB2 AKT1
42	CXCR3-mediated signaling events ¹	11.23	PIK3CA MTOR AKT1
43	a6b1 and a6b4 Integrin signaling ¹	11.18	PIK3CA ERBB2 AKT1
44	PI3K-AKT-mTOR signaling pathway and therapeutic opportunities ¹	11.15	PIK3CA MTOR AKT1
45	Extracellular vesicle-mediated signaling in recipient cells ¹	11.13	MTOR ERBB2 AKT1
46	Plasma membrane estrogen receptor signaling ¹	11.02	PIK3CA ESR1 AKT1
47	E-cadherin signaling in keratinocytes ¹	10.99	PIK3CA AKT1
48	Nongenotropic Androgen signaling ¹	10.96	PIK3CA AKT1
49	4-hydroxytamoxifen, Dexamethasone, and Retinoic Acids Regulation of p27 Expression ¹	10.96	MTOR AKT1
50	Estrogen signaling pathway ¹	10.91	PIK3CA ESR1 AKT1

Sources

GO Terms for Luminal Breast Carcinoma

Cellular components related to Luminal Breast Carcinoma according to GeneCards Suite gene sharing:

#	Name	GO ID	Score	Top Affiliating Genes
1	nucleus	GO:0005634	9.4	ZNF703 PGR MTOR KRT5 KDM4C HORMAD1

Biological processes related to Luminal Breast Carcinoma according to GeneCards Suite gene sharing:

(show all 20)

#	Name	GO ID	Score	Top Affiliating Genes
1	positive regulation of gene expression	GO:0010628	9.8	MTOR KDM4C GATA3 ERBB2 AKT1
2	negative regulation of gene expression	GO:0010629	9.76	PGR GATA3 ESR1 AKT1
3	positive regulation of DNA-binding transcription factor activity	GO:0051091	9.72	FOXA1 ESR1 AKT1
4	chromatin remodeling	GO:0006338	9.7	GATA3 FOXA1 ESR1
5	positive regulation of peptidyl-serine phosphorylation	GO:0033138	9.67	PIK3CA CD44 AKT1
6	uterus development	GO:0060065	9.59	GATA3 ESR1
7	regulation of myelination	GO:0031641	9.58	MTOR AKT1
8	positive regulation of lipid biosynthetic process	GO:0046889	9.57	MTOR AKT1
9	TOR signaling	GO:0031929	9.54	MTOR GATA3 AKT1
10	negative regulation of macroautophagy	GO:0016242	9.5	PIK3CA MTOR AKT1
11	negative regulation of cell size	GO:0045792	9.48	MTOR AKT1
12	regulation of glycogen biosynthetic process	GO:0005979	9.43	MTOR AKT1
13	mammary gland epithelial cell differentiation	GO:0060644	9.43	ZNF703 ELF5 AKT1
14	positive regulation of protein kinase B signaling	GO:0051897	9.35	PIK3CA MTOR GATA3 ESR1 ERBB2
15	anoikis	GO:0043276	9.33	PIK3CA MTOR AKT1
16	phosphatidylinositol phosphorylation	GO:0046854	9.26	PIK3CA
17	positive regulation of transcription by RNA polymerase III	GO:0045945	9.21	MTOR
18	phosphatidylinositol 3-kinase signaling	GO:0014065	8.92	PIK3CA GATA3 ERBB2 AKT1
19	regulation of transcription by RNA polymerase II	GO:0006357	10.06	KDM4C GATA3 FOXA1 ESR1 ERBB2 ELF5
20	positive regulation of transcription by RNA polymerase II	GO:0045944	10.01	PGR GATA3 FOXA1 ESR1 ELF5 AKT1

Molecular functions related to Luminal Breast Carcinoma according to GeneCards Suite gene sharing:

#	Name	GO ID	Score	Top Affiliating Genes
1	sequence-specific DNA binding	GO:0043565	9.65	PGR GATA3 FOXA1 ESR1 ELF5
2	nitric-oxide synthase regulator activity	GO:0030235	9.16	ESR1 AKT1
3	enzyme binding	GO:0019899	9.02	PREX1 PGR KDM4C ESR1 AKT1
4	phosphatidylinositol-4,5-bisphosphate 3-kinase activity	GO:0046934	8.65	PIK3CA

Sources

Sources for Luminal Breast Carcinoma

¹ BioSystems

² BitterDB

³ CDC

⁴ Cell Signaling Technology

⁵ ClinicalTrials

⁶ ClinVar

⁷ CNVD

⁸ Cochrane Library

⁹ Cosmic

¹⁰ dbSNP

¹¹ DGIdb

¹² Disease Ontology

¹³ diseasecard

¹⁴ DiseaseEnhancer

¹⁵ DISEASES

¹⁶ DrugBank

¹⁷ EFO

¹⁸ ExPASy

¹⁹ FMA

²⁰ GeneAnalytics

²¹ GeneCards

²² GeneGo (Thomson Reuters)

²³ GeneHancer via GeneCards

²⁴ GeneReviews

²⁵ Genetics Home Reference

²⁶ GenomeRNAi

²⁷ GEO DataSets

²⁸ GO

²⁹ GTR

³⁰ HGMD

³¹ HMDB

³² HPO

³³ ICD10

³⁴ ICD10 via Orphanet

³⁵ ICD9CM

³⁶ IUPHAR

³⁷ KEGG

³⁸ LifeMap

³⁹ LncRNADisease

⁴⁰ LOVD

⁴¹ MalaCards

⁴² MedGen

⁴³ MedlinePlus

⁴⁴ MeSH

⁴⁵ MESH via Orphanet

⁴⁶ MGI

⁴⁷ miR2Disease

⁴⁸ NCBI Bookshelf

⁴⁹ NCI

⁵⁰ NCIt

⁵¹ NDF-RT

⁵² NIH Clinical Center

⁵³ NIH Rare Diseases

⁵⁴ NINDS

⁵⁵ Novoseek

⁵⁶ Novus Biologicals

⁵⁷ OMIM

⁵⁸ OMIM via Orphanet

⁵⁹ Orphanet

⁶⁰ PathCards

⁶¹ PharmGKB

⁶² PubMed

⁶³ PubMed Health

⁶⁴ QIAGEN

⁶⁵ R&D Systems

⁶⁶ Reactome

⁶⁷ Sino Biological

⁶⁸ SNOMED-CT

⁶⁹ SNOMED-CT via HPO

⁷⁰ TGDB

⁷¹ Tocris

⁷² UMLS

⁷³ UMLS via Orphanet

⁷⁴ UniProtKB/Swiss-Prot

⁷⁵ Wikipedia